CEL-SCI Corp
About: CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
Employees: 44
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
23% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 13
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
0.67% more ownership
Funds ownership: 9.72% [Q3] → 10.38% (+0.67%) [Q4]
8% less funds holding
Funds holding: 66 [Q3] → 61 (-5) [Q4]
53% less capital invested
Capital invested by funds: $6.32M [Q3] → $2.96M (-$3.36M) [Q4]
59% less call options, than puts
Call options by funds: $40K | Put options by funds: $98K
Research analyst outlook
We haven’t received any recent analyst ratings for CVM.
Financial journalist opinion
Based on 5 articles about CVM published over the past 30 days
